Business Description
Cyclacel Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US23254L4059
Description
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 596.4 | |||||
| Equity-to-Asset | -0.18 | |||||
| Debt-to-Equity | -0.01 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -123.36 | |||||
| Beneish M-Score | -4.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 12 | |||||
| 3-Year EPS without NRI Growth Rate | 20 | |||||
| 3-Year FCF Growth Rate | 17 | |||||
| 3-Year Book Growth Rate | -80.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 63.11 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.48 | |||||
| 9-Day RSI | 33.15 | |||||
| 14-Day RSI | 36.51 | |||||
| 6-1 Month Momentum % | -65.19 | |||||
| 12-1 Month Momentum % | -76.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.77 | |||||
| Quick Ratio | 0.77 | |||||
| Cash Ratio | 0.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -36.5 | |||||
| Shareholder Yield % | 2.69 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -20994.6 | |||||
| Net Margin % | -18150 | |||||
| FCF Margin % | -14201.47 | |||||
| ROE % | -2462.6 | |||||
| ROA % | -163.64 | |||||
| ROIC % | -971.44 | |||||
| ROC (Joel Greenblatt) % | -17731.74 | |||||
| ROCE % | -2732.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.61 | |||||
| EV-to-EBIT | 0.06 | |||||
| EV-to-EBITDA | 0.06 | |||||
| EV-to-Revenue | -11.56 | |||||
| EV-to-Forward-Revenue | 0.03 | |||||
| EV-to-FCF | 0.09 | |||||
| Earnings Yield (Greenblatt) % | 1768.75 | |||||
| FCF Yield % | -505.92 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cyclacel Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.068 | ||
| EPS (TTM) (€) | -8.632 | ||
| Beta | -1.15 | ||
| Volatility % | 64.97 | ||
| 14-Day RSI | 36.51 | ||
| 14-Day ATR (€) | 0.006194 | ||
| 20-Day SMA (€) | 0.55 | ||
| 12-1 Month Momentum % | -76.55 | ||
| 52-Week Range (€) | 0.55 - 3.06 | ||
| Shares Outstanding (Mil) | 6.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cyclacel Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cyclacel Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cyclacel Pharmaceuticals Inc Frequently Asked Questions
What is Cyclacel Pharmaceuticals Inc(STU:UXI)'s stock price today?
The current price of STU:UXI is €0.55. The 52 week high of STU:UXI is €3.06 and 52 week low is €0.55.
When is next earnings date of Cyclacel Pharmaceuticals Inc(STU:UXI)?
The next earnings date of Cyclacel Pharmaceuticals Inc(STU:UXI) is 2025-03-19 Est..
Does Cyclacel Pharmaceuticals Inc(STU:UXI) pay dividends? If so, how much?
Cyclacel Pharmaceuticals Inc(STU:UXI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers